Literature DB >> 17266963

Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis.

Cecilia P Chung1, Annette Oeser, Joseph F Solus, Ingrid Avalos, Tebeb Gebretsadik, Ayumi Shintani, Paolo Raggi, Tuulikki Sokka, Theodore Pincus, C Michael Stein.   

Abstract

Patients with rheumatoid arthritis (RA) have accelerated atherosclerosis. The metabolic syndrome, a cluster of cardiovascular risk factors, identifies cardiovascular risk. We tested the hypotheses that patients with RA have a higher prevalence of the metabolic syndrome, particularly the WHO-defined syndrome that requires insulin resistance, and that this is associated with coronary atherosclerosis. The prevalence of the metabolic syndrome was determined using the modified WHO and NCEP III criteria in 154 patients with RA (88 with early RA and 66 with long-standing RA) and 85 control subjects. Coronary-artery atherosclerosis was detected by electron beam computed tomography. The WHO-defined metabolic syndrome was present in 42% of patients with long-standing RA, 31% with early RA and 11% of controls (P<0.001); the NCEP-defined metabolic syndrome was present in 42% of patients with long-standing RA, 30% with early RA and 22% of controls (P=0.03). Patients with the WHO-defined metabolic syndrome had an increased risk of having higher coronary-artery calcification scores, independent of age and sex (OR=2.02, 95% CI: 1.03-3.97, P=0.04). In conclusion, patients with RA have a higher prevalence of the metabolic syndrome than control subjects. Inflammation-associated metabolic syndrome is a mechanism that may contribute to increased coronary-artery atherosclerosis in RA.

Entities:  

Mesh:

Year:  2007        PMID: 17266963     DOI: 10.1016/j.atherosclerosis.2007.01.004

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  112 in total

Review 1.  The role of the T cell in age-related inflammation.

Authors:  Richard Macaulay; Arne N Akbar; Sian M Henson
Journal:  Age (Dordr)       Date:  2012-01-15

2.  Inflammation and hypertension in rheumatoid arthritis.

Authors:  Siriporn Manavathongchai; Aihua Bian; Young Hee Rho; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  J Rheumatol       Date:  2013-09-01       Impact factor: 4.666

Review 3.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

4.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 5.  Rheumatoid arthritis and cardiovascular disease.

Authors:  Mary Chester M Wasko
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

6.  Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?

Authors:  Raquel Cuchacovich; Luis R Espinoza
Journal:  Clin Rheumatol       Date:  2009-06-11       Impact factor: 2.980

7.  Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Ann-Charlotte Elkan; Niclas Håkansson; Johan Frostegård; Tommy Cederholm; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

8.  Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Karen M J Douglas; Helen R Griffiths; George D Kitas
Journal:  Arthritis Res Ther       Date:  2008-12-17       Impact factor: 5.156

9.  Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Holly John; Karen M J Douglas; George D Kitas
Journal:  Arthritis Res Ther       Date:  2009-07-16       Impact factor: 5.156

10.  Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors.

Authors:  Young Hee Rho; Annette Oeser; Cecilia P Chung; Ginger L Milne; C Michael Stein
Journal:  Arch Drug Inf       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.